Zymeworks Included to Nasdaq Biotechnology Index

Write-up material

VANCOUVER, British Columbia, Dec. 15, 2023 (Globe NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a scientific-phase biotechnology enterprise establishing novel, multifunctional biotherapeutics, today declared it is predicted to be included to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). Zymeworks’ addition to the NBI will grow to be efficient prior to the sector open up on Monday, December 18, 2023.

The NBI is designed to monitor the effectiveness of a established of securities shown on The Nasdaq Stock Market place that are issued by companies categorised as both biotechnology or pharmaceutical firms according to the Marketplace Classification Benchmark. Providers in the NBI must meet up with sure eligibility requirements, which include, but not limited to, minimal current market capitalization, average day-to-day trading volume, and seasoning as a general public business. The NBI is evaluated yearly in December and is calculated beneath a modified capitalization-weighted methodology. The NBI is at this time comprised of roughly 250 organizations. For a lot more details about the NBI, go to: https://indexes.nasdaqomx.com/Index/Overview/NBI

Short article articles

About Zymeworks Inc.

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology business dedicated to the discovery, progress, and commercialization of novel, multifunctional biotherapeutics. Zymeworks’ mission is to make a significant variation for people today impacted by hard-to-treat cancers and other really serious conditions. Zymeworks’ complementary therapeutic platforms and thoroughly integrated drug development engine provide the adaptability and compatibility to specifically engineer and acquire really differentiated antibody-primarily based therapeutic candidates. Zymeworks engineered and made zanidatamab, a HER2-specific bispecific antibody working with Zymeworks’ proprietary Azymetric™ technologies. Zymeworks has entered into individual agreements with BeiGene, Ltd. (BeiGene) and Jazz Prescribed drugs Ireland Limited (Jazz), granting every of BeiGene and Jazz with exceptional legal rights to establish and commercialize zanidatamab in diverse territories. Zanidatamab is at the moment being evaluated in worldwide Phase 1, Phase 2, and Section 3 scientific trials, together with certain ongoing pivotal medical trials as a treatment for clients with HER2-expressing cancers. Zymeworks’ future clinical applicant, zanidatamab zovodotin (ZW49), is a HER2-qualified bispecific antibody-drug conjugate (ADC) designed working with Zymeworks’ proprietary Azymetric™ and ZymeLink™ Auristatin technologies. Zanidatamab zovodotin is currently being evaluated in a Section 1 medical demo for people with a wide range of HER2-expressing, HER2-amplified or HER2-mutant cancers. Zymeworks is also advancing a deep pipeline of product or service candidates primarily based on its encounter and abilities in both of those ADC and multispecific antibodies (MSAT). In addition to Zymeworks’ wholly owned pipeline, its therapeutic platforms have been additional leveraged through strategic partnerships with world wide biopharmaceutical organizations. For details about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

Report material

Cautionary Notice Pertaining to Forward-Searching Statements

This push launch consists of “forward-seeking statements” or data inside the this means of the relevant securities legislation, which include Segment 27A of the Securities Act of 1933, as amended, and Area 21E of the Securities Exchange Act of 1934, as amended. Ahead-looking statements in this press launch incorporate, but are not constrained to, statements that relate to the predicted inclusion in the Nasdaq Biotechnology Index following the annual reconstitution, pitfalls and uncertainties relating to the anticipated trading of Zymeworks securities, and other information and facts that is not historic details. When made use of herein, words such as “plan”, “believe”, “expect”, “may”, “continue”, “anticipate”, “potential”, “will”, “progress”, and identical expressions are intended to identify forward-on the lookout statements. In addition, any statements or information and facts that refer to expectations, beliefs, plans, projections, aims, functionality or other characterizations of long term functions or instances, including any fundamental assumptions, are forward-on the lookout. All ahead-looking statements are primarily based on Zymeworks’ recent expectations and a variety of assumptions. Zymeworks believes there is a affordable basis for its anticipations and beliefs, but they are inherently uncertain. Zymeworks may perhaps not notice its anticipations, and its beliefs could not verify suitable. Precise outcomes could vary materially from people described or implied by these types of ahead-seeking statements as a result of a variety of factors, like, devoid of limitation: pitfalls relating to getting integrated and remaining incorporated in the Nasdaq Biotechnology Index pitfalls and uncertainties relating to the investing of our securities as it relates to the Nasdaq Biotechnology Index annual reconstitution and the inclusion of Zymeworks on the Nasdaq Biotechnology Index next these kinds of reconstitution clinical trials might not reveal safety and efficacy of any of Zymeworks’ or its collaborators’ solution candidates any of Zymeworks’ or its partners’ product candidates may well fall short in growth, might not obtain expected regulatory approvals, or may perhaps be delayed to a position exactly where they are not commercially feasible Zymeworks may perhaps not realize milestones or acquire supplemental payments underneath its collaborations the affect of pandemics and other wellness crises on Zymeworks’ enterprise, analysis and scientific growth strategies and timelines and effects of operations, which include affect on its medical trial sites, collaborators, and contractors who act for or on Zymeworks’ behalf incapacity to preserve or enter into new partnerships or strategic collaborations regulatory businesses may perhaps impose more prerequisites or delay the initiation of clinical trials the impression of new or shifting legal guidelines and rules current market problems and the other challenges described less than “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter finished September 30, 2023 (a copy of which may perhaps be received at www.sec.gov and www.sedar.com). Though Zymeworks believes that this kind of ahead-on the lookout statements are fair, there can be no assurance they will show to be suitable. Investors really should not location undue reliance on ahead-looking statements. The over assumptions, dangers and uncertainties are not exhaustive. Ahead-looking statements are made as of the day hereof and, besides as may perhaps be required by legislation, Zymeworks undertakes no obligation to update, republish, or revise any ahead-looking statements to replicate new data, upcoming functions or instances, or to mirror the occurrences of unanticipated gatherings.

Contacts:

Investor Inquiries:

Shrinal Inamdar
Director, Investor Relations
(604) 678-1388
[email protected]   

Media Inquiries:

Diana Papove
Director, Company Communications
(604) 678-1388
[email protected]

Share this post in your social community